UT
The startup develops cancer treatments using proprietary technologies, including a T-cell enhancing platform, mRNA therapies, and an antibody affinity optimization platform. These modalities provide patients with targeted drug options to improve treatment efficacy and outcomes.
Updated 2 months ago
Funding
$82.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops cancer treatments using proprietary technologies, including a T-cell enhancing platform, mRNA therapies, and an antibody affinity optimization platform. These modalities provide patients with targeted drug options to improve treatment efficacy and outcomes.